Boston Scientific Co. (NYSE:BSX) Shares Bought by Sachetta LLC

Sachetta LLC boosted its stake in Boston Scientific Co. (NYSE:BSX) by 157.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,450 shares of the medical equipment provider’s stock after acquiring an additional 887 shares during the quarter. Sachetta LLC’s holdings in Boston Scientific were worth $130,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Global Wealth Strategies & Associates increased its position in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 250 shares in the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $29,000. Dunhill Financial LLC boosted its holdings in Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 152 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Boston Scientific during the 3rd quarter worth $28,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new position in Boston Scientific in the third quarter valued at about $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.3 %

Shares of BSX stock opened at $101.97 on Friday. The business has a 50-day moving average price of $91.96 and a two-hundred day moving average price of $85.16. Boston Scientific Co. has a 12-month low of $59.97 and a 12-month high of $102.15. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market cap of $150.29 billion, a P/E ratio of 84.28, a price-to-earnings-growth ratio of 2.63 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the prior year, the firm earned $0.50 earnings per share. Boston Scientific’s revenue for the quarter was up 19.3% on a year-over-year basis. Equities analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BSX. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. StockNews.com cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Morgan Stanley upped their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. TD Cowen raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, Canaccord Genuity Group upped their target price on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $97.26.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares of the company’s stock, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock worth $2,702,261 in the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.